Most importantly, the ATAD3A-ERK1/2 signaling axis drives HNSCC development in a RAS-independent manner, and thus tumor suppression is more effective when ATAD3A knockout is combined with RAS inhibitor treatment. The gene discussed is ATAD3A; the disease is neoplasm.